MYIA
ABCL icon

Mount Yale Investment Advisors’s AbCellera Biologics ABCL Stock Holding History

Mount Yale Investment Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,905
Closed -$6.53K – 678
2025
Q2 		$6.53K Buy
+1,905
New +$4.74K ﹤0.01% 1193

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Mount Yale Investment Advisors's ABCL Position: Q3 2025 in Review

Mount Yale Investment Advisors sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 1,905 shares — an estimated $6.53K sold.

Mount Yale Investment Advisors first reported a position in ABCL in Q2 2025 and held it in 1 quarter. The position peaked at $6.53K in Q2 2025. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

  • Mount Yale Investment Advisors reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 1,905 AbCellera Biologics shares in Q3 2025, an estimated $6.53K.
  • Mount Yale Investment Advisors first reported a position in AbCellera Biologics in Q2 2025 and held it in 1 quarter.
  • Mount Yale Investment Advisors's AbCellera Biologics position peaked at $6.53K in Q2 2025.
  • 141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on Mount Yale Investment Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.